Basel, 17 July 2018 Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu Baloxavir marboxil – an investigational oral, single-dose antiviral – is the first flu medicine with a novel proposed mechanism of action in nearly 20 years and to demonstrate significant efficacy in... Read more
Basel, 12 July 2018 Roche announces submission of supplemental New Drug Application for Venclexta for people with previously untreated acute myeloid leukaemia who are ineligible for intensive chemotherapy Venclexta represents a potential new way of treating AML, the most common type of aggressive leukaemia in adults1 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced submission... Read more
Basel, 11 July 2018 Invitation to Roche’s Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 2 August 2018, featuring... Read more
Basel, 03 July 2018 Invitation to Roche Analyst Event on Diagnostics Division at AACC 2018 Tuesday, 31st July 2018, 6:00pm CDT We are pleased to invite you to an analyst event on Tuesday, 31st July 2018 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical... Read more
Basel, 02 July 2018 Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at a... Read more
Basel, 02 July 2018 Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer First Phase III immunotherapy study to demonstrate a statistically significant improvement in progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1 positive first-line metastatic triple... Read more
Basel, 29 June 2018 Roche’s RoActemra gains positive CHMP opinion for CAR T-cell-induced cytokine release syndrome Cytokine release syndrome (CRS), a severe and life-threatening condition, is caused by an overactive immune response and is often associated with the use of chimeric antigen receptor (CAR) T-cell therapy for certain blood cancers RoActemra would be the first... Read more
Basel, 26 June 2018 FDA grants Priority Review to Roche’s baloxavir marboxil for the treatment of influenza Influenza, or “flu,” represents a serious threat to public health – globally, annual epidemics result in 3 to 5 million cases of severe disease, millions of hospitalisations and up to 650,000 deaths worldwide1,2,3,4,5 If approved, baloxavir marboxil would... Read more
Basel, 25 June 2018 Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy IMpower133 is the first Phase III study with an immunotherapy-based combination to show improvement in overall survival and progression-free survival in the initial treatment of extensive-stage small cell lung cancer... Read more
Basel, 25 June 2018 Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy IMpower133 is the first Phase III study with an immunotherapy-based combination to show improvement in overall survival and progression-free survival in the initial treatment of extensive-stage small cell lung cancer... Read more